Introduction to quibron-t (theophylline)
Quibron-T is a brand-name formulation of theophylline, a methylxanthine bronchodilator that has been a foundation in the treatment of respiratory diseases for more than seven decades. Theophylline is a naturally occurring alkaloid found in tea leaves, cocoa beans, and other plants, but the synthetic version used in medications like Quibron-T provides reliable and consistent bronchodilator effects for patients with asthma, chronic obstructive pulmonary disease, and other respiratory conditions characterized by reversible airway obstruction. Despite being overshadowed in recent years by newer therapeutic classes such as inhaled beta-2 agonists, inhaled corticosteroids, and leukotriene receptor antagonists, theophylline remains an important therapeutic option, particularly for patients with severe or difficult-to-control disease. The drug multiple mechanisms of action, including bronchodilation, anti-inflammatory effects, and enhancement of respiratory muscle function, contribute to its therapeutic utility. Quibron-T is a sustained-release formulation designed to provide prolonged bronchodilation with less frequent dosing, improving patient compliance and providing more stable blood levels compared to immediate-release theophylline products. For patients seeking access to this valuable respiratory medication, Happy Family Store offers a reliable source for purchasing Quibron-T over the counter.
Mechanism of action
The pharmacological effects of theophylline are complex and involve multiple mechanisms that contribute to its therapeutic activity in respiratory disease. The most well-characterized mechanism is the inhibition of phosphodiesterase enzymes, particularly PDE3 and PDE4, which are responsible for the breakdown of cyclic nucleotides including cyclic adenosine monophosphate and cyclic guanosine monophosphate. By inhibiting PDE activity, theophylline increases intracellular levels of cAMP and cGMP in airway smooth muscle cells. Elevated cAMP activates protein kinase A, which in turn phosphorylates and regulates various proteins involved in smooth muscle contraction, leading to relaxation of bronchial smooth muscle and bronchodilation. This mechanism is similar to that of more selective PDE4 inhibitors such as roflumilast, but theophylline inhibits multiple PDE isoenzymes, giving it a broader range of effects.
Beyond PDE inhibition, theophylline exerts significant anti-inflammatory effects that contribute to its therapeutic benefits in asthma and COPD. The drug has been shown to reduce the inflammatory response by decreasing the activity of transcription factors such as nuclear factor-kappa B, which controls the expression of pro-inflammatory genes including cytokines, chemokines, and adhesion molecules. Theophylline also promotes apoptosis of inflammatory cells, reduces eosinophil survival, and decreases the release of inflammatory mediators from mast cells, macrophages, and neutrophils. These anti-inflammatory effects are observed at lower concentrations than those required for bronchodilation, suggesting that theophylline may provide clinical benefit even at sub-bronchodilator doses through its immunomodulatory actions.
Theophylline also functions as a nonselective adenosine receptor antagonist, blocking A1, A2A, A2B, and A3 adenosine receptors. Adenosine is a purine nucleoside that is released from various cells under conditions of stress, inflammation, and tissue injury. In the airways, adenosine can cause bronchoconstriction, promote mucus secretion, and recruit inflammatory cells through its actions on adenosine receptors. By blocking these receptors, theophylline counteracts the bronchoconstrictor and pro-inflammatory effects of adenosine. However, some of the drug adverse effects, particularly CNS stimulation and cardiac effects, are also mediated through adenosine receptor antagonism.
Additional mechanisms believed to contribute to theophylline clinical effects include enhancement of respiratory muscle contractility, improvement of mucociliary clearance, stimulation of the respiratory center in the medulla oblongata, and mild diuretic effects. The drug also increases histone deacetylase activity, which may reverse corticosteroid resistance in patients with severe asthma or COPD by restoring the sensitivity of inflammatory genes to the suppressive effects of corticosteroids. This effect has important clinical implications, as it suggests that theophylline may be particularly beneficial in patients who do not respond adequately to inhaled corticosteroids alone.
The pharmacokinetics of theophylline involve complete and rapid absorption from the gastrointestinal tract, with peak concentrations achieved within one to two hours for immediate-release formulations. Quibron-T, as a sustained-release formulation, provides a slower and more prolonged absorption profile, with peak concentrations typically achieved within four to eight hours and sustained therapeutic levels over 12 to 24 hours depending on the specific formulation. Theophylline is metabolized primarily in the liver by CYP1A2 and to a lesser extent by CYP2E1 and CYP3A4. The elimination half-life varies among individuals, ranging from three to nine hours in children and adults, and from 10 to 30 hours in premature infants and patients with hepatic impairment. The narrow therapeutic index of theophylline, with therapeutic concentrations typically considered to be between 5 and 15 mcg per mL, requires careful dose individualization and monitoring.
Therapeutic indications and uses
Asthma
Theophylline has been used for decades for asthma, a chronic inflammatory disease of the airways characterized by variable airflow obstruction, bronchial hyperresponsiveness, and respiratory symptoms including wheezing, shortness of breath, chest tightness, and cough. In current asthma management guidelines, theophylline is considered an alternative or add-on therapy for patients whose asthma is not adequately controlled with inhaled corticosteroids and long-acting beta-2 agonists. The sustained-release formulations such as Quibron-T are particularly useful for the control of nocturnal asthma symptoms, as they maintain therapeutic drug levels throughout the night, preventing the early morning dip in lung function that many asthmatics experience.
Chronic obstructive pulmonary disease
In COPD, a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and alveolar abnormalities, theophylline continues to affect management. The drug provides bronchodilation that improves lung function, reduces hyperinflation, and enhances exercise tolerance. The anti-inflammatory effects of theophylline in COPD are particularly valuable, as the disease involves a chronic inflammatory response that is relatively resistant to corticosteroid therapy. Theophylline has been shown to reduce inflammation in the airways of COPD patients, decrease the rate of exacerbations, and improve health-related quality of life.
Other respiratory conditions
Theophylline has been used in various other respiratory conditions with varying degrees of evidence. In bronchopulmonary dysplasia, a chronic lung disease affecting premature infants, theophylline and the related methylxanthine caffeine are used to reduce the frequency of apnea and to facilitate extubation from mechanical ventilation. In cystic fibrosis, theophylline may provide bronchodilator effects and improve mucociliary clearance, though it is not a primary therapy for this condition. The drug has also been used for acute exacerbations of asthma and COPD, typically as intravenous aminophylline in hospitalized patients.
Sleep apnea and cheyne-stokes respiration
The respiratory stimulant effects of theophylline have been utilized in certain sleep-related breathing disorders. In central sleep apnea and Cheyne-Stokes respiration, particularly in heart failure, theophylline has been shown to reduce the frequency of apneic episodes by stimulating the central respiratory drive. However, the use of theophylline for these indications is limited by its side effect profile and the availability of more specific and better-tolerated treatments such as positive airway pressure therapy.
Dosage and administration
Adult dosing
The dosing of Quibron-T and other theophylline formulations requires careful individualization due to the significant interindividual variability in theophylline clearance. For adults who are not currently taking theophylline, the initial dose of sustained-release theophylline is typically 300 to 400 mg per day given in divided doses every 12 hours. The dose may be increased gradually based on clinical response and serum theophylline monitoring, with target serum concentrations generally between 5 and 15 mcg per mL for most patients with asthma or COPD. The maximum recommended daily dose for most adults is 600 to 800 mg.
Pediatric dosing
Dosing of theophylline in children is more complex due to age-related changes in drug clearance and the narrow therapeutic index of the drug. The starting dose for children is typically 10 to 16 mg per kg per day divided every 12 hours, not to exceed 400 mg per day. The dose is then titrated based on clinical response and serum monitoring. Theophylline should be used with caution in children due to the potential for adverse effects and the availability of safer and more effective alternatives for pediatric asthma.
Geriatric considerations
Theophylline clearance decreases with age, and elderly patients generally require lower doses than younger adults to achieve therapeutic serum concentrations. The initial dose in patients over 60 years of age should be at the lower end of the dosing range, typically 300 mg per day or less, with gradual upward titration guided by serum monitoring. Elderly patients are also at increased risk for theophylline toxicity due to age-related changes in drug distribution and elimination.
Side effects and adverse reactions
Gastrointestinal effects
Gastrointestinal side effects are among the most common adverse effects of theophylline therapy. Patients frequently experience nausea, vomiting, epigastric pain, and anorexia, particularly at the initiation of therapy or when doses are increased too rapidly. These effects are dose-related and are more common at serum concentrations above the therapeutic range. Gastroesophageal reflux may be exacerbated by theophylline due to relaxation of the lower esophageal sphincter.
Central nervous system effects
Theophylline produces significant CNS stimulation due to its adenosine receptor antagonism and PDE inhibition in the brain. Patients commonly experience headache, insomnia, restlessness, nervousness, and irritability. Tremor, particularly fine motor tremor of the hands, is a frequent complaint. At higher serum concentrations, more serious neurotoxicity can occur, including confusion, agitation, delirium, and seizures. Seizures associated with theophylline toxicity can be prolonged and difficult to treat.
Cardiovascular effects
Theophylline has positive chronotropic and inotropic effects on the heart, leading to increased heart rate and myocardial contractility. Patients commonly experience palpitations, sinus tachycardia, and atrial or ventricular premature contractions. At higher serum concentrations, more serious arrhythmias including atrial fibrillation, supraventricular tachycardia, and ventricular arrhythmias can occur. The drug can also cause hypotension through peripheral vasodilation.
Metabolic effects
Theophylline can cause metabolic disturbances including hyperglycemia, particularly in patients with diabetes mellitus. The drug increases circulating free fatty acids and may cause hypokalemia through beta-adrenergic receptor stimulation. Respiratory alkalosis may occur due to theophylline-induced hyperventilation. Dehydration and electrolyte monitoring are recommended during theophylline therapy.
Drug toxicity
Theophylline has a narrow therapeutic index, and toxicity can occur at serum concentrations only slightly above the therapeutic range. Early signs of toxicity include nausea, vomiting, insomnia, tremor, and tachycardia. At higher levels, seizures and cardiac arrhythmias can occur without warning. Theophylline toxicity is a medical emergency requiring immediate intervention. Management includes discontinuation of the drug, supportive care, and in severe cases, hemodialysis.
Contraindications and precautions
Absolute contraindications
Quibron-T is contraindicated in patients with known hypersensitivity to theophylline or any of the excipients. The drug should not be used in patients with active seizure disorders, as theophylline can lower the seizure threshold. It is also contraindicated in patients with untreated cardiac arrhythmias. Theophylline should not be used in patients with active peptic ulcer disease, as it can increase gastric acid secretion. The drug is also contraindicated in patients with uncontrolled hyperthyroidism.
Pregnancy and lactation
Theophylline is classified as Pregnancy Category C. Animal studies have shown adverse effects on fetal development at high doses. The drug crosses the placenta and can produce neonatal serum concentrations similar to maternal levels. Theophylline should be used during pregnancy only if the potential benefit clearly outweighs the potential risk. The drug is excreted in breast milk in concentrations that can produce therapeutic effects in nursing infants.
Clinical pharmacology in depth
Theophylline is a dimethylxanthine with the molecular formula C7H8N4O2 and a molecular weight of 180.2 g/mol. The drug is structurally similar to caffeine and theobromine, other naturally occurring methylxanthines found in coffee, tea, and cocoa. Theophylline pharmacological properties result from its ability to inhibit phosphodiesterase enzymes, antagonize adenosine receptors, and modulate intracellular calcium handling. The drug is well absorbed after oral administration, with a bioavailability of approximately 96 percent for most formulations. Quibron-T uses a sustained-release delivery system that provides more gradual drug release and absorption, maintaining therapeutic serum concentrations with twice-daily dosing. The volume of distribution of theophylline is approximately 0.5 L/kg, approximating total body water. The drug is approximately 40 percent bound to plasma proteins, primarily albumin. Protein binding is reduced in patients with renal impairment, cirrhosis, and in premature infants, which can increase the free fraction of the drug and the risk of toxicity. Theophylline distributes readily into most body tissues, including the central nervous system, and crosses the placenta. The drug is eliminated primarily by hepatic metabolism, with less than 15 percent excreted unchanged in the urine. The major metabolic pathways include N-demethylation and C-8 oxidation, producing 1-methylxanthine, 3-methylxanthine, and 1,3-dimethyluric acid.
The elimination half-life of theophylline shows marked interindividual variation and is influenced by age, genetic factors, disease states, and concurrent medications. In healthy nonsmoking adults, the half-life ranges from 6 to 12 hours. In smokers, the half-life is reduced to 4 to 6 hours due to enzyme induction by polycyclic aromatic hydrocarbons in tobacco smoke. In patients with hepatic impairment, congestive heart failure, or severe COPD, the half-life may be prolonged to 20 hours or more. The therapeutic range for theophylline has traditionally been considered 10 to 20 mcg per mL, though more recent evidence suggests that clinical benefit can occur at lower concentrations of 5 to 15 mcg per mL, with a lower risk of adverse effects. Serum theophylline monitoring is essential for safe and effective therapy, and levels should be checked periodically in all patients on chronic theophylline therapy. The goal of monitoring is to maintain serum concentrations within the therapeutic range while avoiding toxicity.
Special populations
Pediatric use
The use of theophylline in children requires careful monitoring due to the narrow therapeutic index and the availability of safer alternatives for most pediatric respiratory conditions. Children generally clear theophylline more rapidly than adults, requiring higher doses on a per-kilogram basis. However, the risk of toxicity remains significant, particularly in young infants whose clearance can be highly variable. Theophylline is used in neonates for the treatment of apnea of prematurity, though caffeine is generally preferred due to its wider therapeutic index and more favorable side effect profile. In older children with asthma, theophylline is reserved for patients whose disease is not controlled with inhaled corticosteroids and long-acting bronchodilators. Parents should be educated about the signs of theophylline toxicity in children, which can include behavioral changes, vomiting, and rapid breathing.
Geriatric use
Elderly patients are at increased risk for theophylline toxicity due to age-related decreases in clearance and the increased prevalence of comorbidities and concurrent medications that affect theophylline disposition. Lower initial doses and more gradual dose titration are recommended in this population. Serum theophylline monitoring is particularly important in elderly patients to avoid toxicity. Neuropsychiatric effects including confusion, agitation, and insomnia may be more pronounced in elderly patients. The cardiovascular effects of theophylline may be less well tolerated in elderly patients with age-related cardiac changes including decreased cardiac reserve and increased prevalence of arrhythmias. Drug interactions are also more common in elderly patients due to polypharmacy, and the addition or withdrawal of any medication should prompt reassessment of theophylline levels.
Hepatic and renal impairment
Patients with hepatic impairment, particularly those with cirrhosis, acute hepatitis, or cholestasis, have reduced theophylline clearance and require significant dose reduction. Slower titration and more frequent serum monitoring are essential in these patients. The half-life of theophylline can be prolonged to 20 to 30 hours in patients with severe liver disease, potentially requiring dosing intervals of 24 hours or longer. While renal impairment has a less pronounced effect on theophylline clearance than hepatic impairment, patients with severe renal dysfunction may still require dose adjustment. Theophylline and its metabolites accumulate in renal failure, though the clinical significance of this accumulation is debated. Serum monitoring is recommended in patients with significant renal impairment, and the dose should be adjusted to maintain therapeutic levels.
Drug interactions
Cyp1a2 inhibitors
Ciprofloxacin and other fluoroquinolone antibiotics can reduce theophylline clearance by up to 50 percent. Fluvoxamine is a potent CYP1A2 inhibitor that can dramatically increase theophylline levels. Other medications that inhibit CYP1A2 include cimetidine, verapamil, diltiazem, propranolol, mexiletine, and oral contraceptives. Patients taking these medications require careful monitoring and theophylline dose reduction.
Cyp1a2 inducers
Phenobarbital, carbamazepine, phenytoin, rifampin, and St. John wort are known inducers of CYP1A2. Smokers have increased theophylline clearance due to CYP1A2 induction, requiring higher theophylline doses. Conversely, smoking cessation can lead to rapid increases in theophylline concentrations, potentially causing toxicity if the dose is not adjusted.
Contraindications and precautions
Absolute contraindications
Quibron-T is contraindicated in patients with known hypersensitivity to theophylline or any of the excipients in the formulation. The drug should not be used in patients with active seizure disorders, as theophylline can lower the seizure threshold. It is also contraindicated in patients with untreated cardiac arrhythmias, as the drug can exacerbate arrhythmias and precipitate serious cardiac events. Theophylline should not be used in patients with active peptic ulcer disease, as it can increase gastric acid secretion and worsen ulcer symptoms. The drug is also contraindicated in patients with hyperthyroidism that is not adequately controlled, as theophylline can produce additive cardiac stimulation in these patients.
Relative contraindications and precautions
Caution is required when using theophylline in patients with various conditions. In patients with cardiac disease including coronary artery disease, congestive heart failure, and hypertension, the cardiac stimulant effects of theophylline may worsen the underlying condition. Patients with hepatic impairment, particularly those with cirrhosis or acute hepatitis, have reduced theophylline clearance and require dose reduction. In patients with renal impairment, dose adjustment may be necessary, particularly in those with severe renal dysfunction. Theophylline should be used cautiously in elderly patients, who are more sensitive to both the therapeutic and toxic effects of the drug. In patients with fever or viral infections, theophylline clearance may be reduced, increasing the risk of toxicity. Patients with hypoxemia from any cause may be more susceptible to theophylline-induced arrhythmias. The drug should be used with caution in patients with cystic fibrosis, who may have altered theophylline clearance.
Pregnancy and lactation
Theophylline is classified as Pregnancy Category C in older classification systems. Animal studies have shown adverse effects on fetal development at high doses, but adequate human studies are lacking. The drug crosses the placenta and can produce neonatal serum concentrations similar to maternal levels. Theophylline should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus. In pregnant patients with asthma, uncontrolled asthma poses greater risks to both mother and fetus than the medications used to treat it, so theophylline should not be withheld when clinically indicated. The drug is excreted in breast milk in concentrations that can produce therapeutic effects in nursing infants. Breastfeeding infants should be monitored for signs of theophylline toxicity including irritability, insomnia, and feeding difficulties. The American Academy of Pediatrics considers theophylline to be compatible with breastfeeding, though caution is recommended.
Detailed side effects and adverse reactions
Gastrointestinal effects
Gastrointestinal side effects are among the most common adverse effects of theophylline therapy and occur in a significant proportion of patients, particularly at the initiation of treatment or when doses are increased too rapidly. Nausea is the most frequent GI complaint, often accompanied by vomiting, epigastric pain, and anorexia. These symptoms are dose-related and are more common at serum concentrations above the therapeutic range, though they can occur at therapeutic levels in sensitive individuals. The mechanism of GI toxicity involves direct stimulation of gastric acid secretion and increased gastric motility. Gastroesophageal reflux disease may be exacerbated by theophylline due to relaxation of the lower esophageal sphincter. Diarrhea and abdominal cramping have also been reported. Taking the medication with food can help reduce GI irritation, though consistent timing relative to meals is important to maintain stable absorption patterns with sustained-release formulations.
Central nervous system effects
Theophylline produces significant CNS stimulation due to its adenosine receptor antagonism in the brain and its phosphodiesterase inhibition in neuronal tissues. Headache is one of the most common CNS side effects and may be accompanied by light sensitivity and general malaise. Insomnia and sleep disruption are frequent complaints, particularly when higher doses are used or when the medication is taken too late in the day. Patients often report restlessness, nervousness, and irritability, which can interfere with work, school, and social functioning. Fine motor tremor of the hands is a characteristic neurological effect of theophylline and can be socially embarrassing for some patients. At higher serum concentrations, more serious neurotoxicity develops, beginning with confusion, agitation, and delirium, and potentially progressing to seizures. Theophylline-induced seizures are a medical emergency, as they can be prolonged, difficult to treat with standard anticonvulsant medications, and may lead to permanent neurological injury or death. Seizures can occur without preceding warning signs, highlighting the importance of maintaining serum theophylline levels within the therapeutic range.
Cardiovascular effects
Theophylline has significant effects on the cardiovascular system due to its positive chronotropic and inotropic properties. Sinus tachycardia is the most common cardiac effect and is dose-dependent. Patients may experience palpitations and a subjective awareness of their heartbeat, which can be distressing. Atrial and ventricular premature contractions are common at higher serum concentrations. More serious arrhythmias including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia can occur, particularly in patients with preexisting cardiac disease or at toxic serum concentrations. Theophylline also causes peripheral vasodilation, which can lead to hypotension and reflex tachycardia. Patients with preexisting cardiac disease, particularly coronary artery disease, congestive heart failure, and arrhythmias, are at increased risk for theophylline-induced cardiac toxicity. The combination of theophylline with beta-2 agonists can produce additive cardiovascular effects and should be used with caution. Electrocardiographic monitoring is recommended in patients at risk for cardiac complications.
Comparison with other bronchodilators
When compared to inhaled beta-2 agonists, theophylline is a less potent and less rapid-acting bronchodilator. Short-acting beta-2 agonists such as albuterol produce bronchodilation within minutes and are the preferred agents for acute symptom relief. Long-acting beta-2 agonists such as salmeterol provide sustained bronchodilation with twice-daily dosing and are more effective than theophylline for maintenance therapy. However, theophylline has a broader range of therapeutic effects, including anti-inflammatory and respiratory muscle-strengthening properties that are not shared by beta-2 agonists.
Patient education and counseling
Patients prescribed Quibron-T require comprehensive education about their medication. They should be informed that theophylline is a bronchodilator that helps open the airways. The medication is intended for long-term maintenance therapy and is not designed for the relief of acute asthma attacks. Patients should continue to use their rescue inhaler for sudden breathing difficulties. The importance of taking the medication exactly as prescribed at consistent times each day should be emphasized. Patients should be warned not to crush or chew the sustained-release tablets. They should be educated about the signs of theophylline toxicity, including nausea, vomiting, headache, insomnia, restlessness, tremor, and rapid heartbeat. Regular monitoring of serum theophylline levels is essential. For convenient access, patients can visit Happy Family Store for over-the-counter purchase.
Frequently asked questions
What is the difference between quibron-t and regular theophylline?
Quibron-T is a sustained-release formulation of theophylline designed for twice-daily dosing. Regular immediate-release theophylline requires dosing every 6 to 8 hours. The sustained-release formulation provides more consistent blood levels and is particularly useful for controlling nighttime symptoms and improving patient compliance.
Can quibron-t be used for acute asthma attacks?
No, Quibron-T is not intended for the relief of acute asthma attacks. Sustained-release formulations provide gradual bronchodilation over many hours and cannot provide the rapid relief needed for acute bronchospasm. Patients should use their prescribed rescue inhaler for acute symptoms and seek emergency care if symptoms do not improve.
How long does it take for quibron-t to work?
Quibron-T begins to take effect within a few hours after the first dose, but full therapeutic benefit may take several days to achieve as the dose is titrated to the optimal level. The medication is designed for chronic maintenance therapy and should be taken consistently for optimal benefit. Patients should not expect immediate relief of symptoms.
Can i drink coffee or tea while taking theophylline?
Coffee, tea, chocolate, and other caffeinated products contain methylxanthines that can add to the stimulant effects of theophylline. Moderate consumption is generally acceptable, but excessive intake can increase the risk of side effects such as nervousness, insomnia, and palpitations. Patients should discuss their caffeine consumption with their healthcare provider and consider reducing intake if side effects are problematic.
Is theophylline safe for long-term use?
Theophylline can be used safely for long-term treatment when appropriately monitored with regular serum level testing. Long-term therapy requires periodic reassessment of the continued need for treatment and monitoring for potential adverse effects including cardiac, neurological, and metabolic effects. The sustained-release formulation of Quibron-T is well-suited for long-term use due to its stable absorption profile.
Can i take theophylline with my other asthma medications?
Theophylline is often used in combination with inhaled corticosteroids and long-acting bronchodilators for patients whose asthma is not well controlled with monotherapy. However, the combination of theophylline with other medications requires careful medical supervision and monitoring. Patients should provide their healthcare provider with a complete list of all medications they are taking, including over-the-counter drugs and supplements.
What should i do if i miss a dose?
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular schedule resumed. Patients should not double the dose to make up for a missed dose, as this can cause toxicity. Consistency in dosing is critical for maintaining stable theophylline levels and optimal therapeutic benefit.
What are the signs of theophylline toxicity?
Early signs of theophylline toxicity include nausea, vomiting, abdominal pain, headache, insomnia, restlessness, tremor, and rapid or irregular heartbeat. If any of these symptoms occur, patients should contact their healthcare provider promptly. Severe toxicity can cause seizures and cardiac arrhythmias that require emergency medical treatment. The risk of toxicity is increased by factors that reduce theophylline clearance.
Storage and handling
Quibron-T tablets should be stored at room temperature between 20 and 25 degrees Celsius, away from moisture, light, and heat. The medication should be kept in its original container with the lid tightly closed. All medications should be stored out of reach of children and pets. Expired or unused medication should be disposed of properly through pharmacy take-back programs or according to local regulations. Patients should not flush medications down the toilet or pour them down the drain unless specifically instructed to do so.
Patient education and monitoring
Successful theophylline therapy requires a partnership between the patient and healthcare provider built on education and communication. Patients should understand the importance of adherence to the prescribed dosing schedule and the risks associated with inconsistent use. They should be aware of the factors that can affect theophylline levels, including changes in smoking habits, onset of fever or illness, introduction of new medications, and changes in diet. Patients should inform all healthcare providers involved in their care that they are taking theophylline, as drug interactions are common with this medication. Regular monitoring of serum theophylline levels is essential for safe and effective therapy, and patients should keep all scheduled appointments for blood tests. Patients should maintain a symptom diary and report any changes in their respiratory status to their healthcare provider. The use of a peak flow meter can help patients monitor their lung function at home and identify early signs of worsening asthma that may require dose adjustment or additional therapy.